Healthcare Industry News: Maquet Cardiovascular
News Release - May 19, 2011
MAQUET Cardiovascular Receives European CE Mark for CARDIOROOT Aortic GraftWAYNE, NJ--(Healthcare Sales & Marketing Network) - Maquet Cardiovascular today announced that it has received European CE Mark approval for its CARDIOROOT aortic graft. An innovative, one-piece design, aortic root graft, CARDIOROOT will be used by vascular and cardiovascular surgeons to surgically repair or replace diseased and damaged aortae. It is expected to be commercially available in the EU within the next 60 days.
"The unique concept of MAQUET CARDIOROOT combines excellent suturability with uncompromised handling. Not only is it easier to implant, but its unique uncrimped shape perfectly matches the aortic root anatomy," said Nicolas Bischoff, M.D., Head of Thoracic and Cardiovascular Surgery at Centre Hospitalier Mulhouse, France.
"We are pleased that the European authorities have approved the use of CARDIOROOT and look forward to commercializing this innovative graft in Europe," said Brad Cilley, Vice President of Marketing for Maquet Cardiovascular. "CARDIOROOT has the outstanding handling and suturability that are the hallmarks of MAQUET surgical grafts, which are used every day in the EU in life-saving procedures. The introduction of CARDIOROOT continues Maquet Cardiovascular's longstanding tradition of providing innovative surgical grafts to cardiothoracic and vascular surgeons to benefit their patients."
MAQUET's Portfolio of Vascular Grafts
All MAQUET vascular grafts are designed for optimal patient outcomes and feature technologies to improve hemostasis, encourage tissue in-growth, promote natural healing and provide long-term durability.
The CARDIOROOT aortic graft is the latest addition to Maquet Cardiovascular's portfolio of market-leading surgical grafts, which includes the HEMASHIELD line of aortic grafts, the most used and most studied vascular grafts in the world cardiothoracic surgical market. More than 2 million HEMASHIELD grafts have been implanted in patients worldwide, with clearly demonstrated clinical efficacy and improved outcomes. MAQUET's INTERGARD grafts include the innovative INTERGARD Knitted grafts with reverse Locknit construction to resist postoperative dilatation, the INTERGARD ULTRATHIN heparin-coated graft, designed to promote graft patency, and INTERGARD SILVER, the world's first antimicrobial surgical graft.
As a trusted partner for hospitals and clinicians since 1838, MAQUET is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. MAQUET develops and designs innovative products and therapeutic applications for the operating room, hybrid OR/cath lab, intensive care unit and patient transport within acute care hospitals, improving outcomes and quality of life for patients.
Cardiovascular specialties include intra-aortic balloon counterpulsation (IABC) therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation. The Critical Care portfolio includes market-leading intensive care ventilators and anesthesia machines. MAQUET also equips Surgical Workplaces with critical infrastructure, such as flexible room design for OR and ICU; OR tables; lights and ceiling supply units; and OR integration for image data management.
MAQUET is a subsidiary of the publicly listed Swedish GETINGE GROUP. In 2010, MAQUET generated nearly half of the company's annual revenue of $3.2 billion. The company has 12,000 employees worldwide, including 5,000 employees in 36 international sales and service organizations, as well as a network of more than 250 sales representatives. For more information please visit www.maquet.com and www.getingegroup.com.
MAQUET -- The Gold Standard.
Source: MAQUET Cardiovascular
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.